Investegate |MGC Pharmaceuticals Announcements | MGC Pharmaceuticals: Quarterly Results investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Bluechiip Ltd (ASX:BCT) Quarterly Activity Report
Quarterly Activity Report Melbourne, April 28, 2021 AEST (ABN Newswire) - Bluechiip Limited (
ASX:BCT), a developer and leader in wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries is pleased to release its Appendix 4C - Quarterly Cashflow report and update for the quarter ended 31 March 2021.
Corporate and Business updates for the Quarter
- Progressive discussions and negotiations with potential OEMs including in the IVF market, Cell Therapy and target Biobanking space with interest for the Company s products;
- Agreed non-binding OEM term sheet following excellent progress made with a new potential OEM partner in the United States (USA);
Bluechiip Ltd (ASX:BCT) Quarterly Activity - Cashflow Report
Quarterly Activity - Cashflow ReportMelbourne, Jan 29, 2021 AEST (ABN Newswire) - Bluechiip Ltd (
ASX:BCT) sales and marketing teams both in Australia and the United States continue to make progressive negotiations with potential OEMs especially in the IVF and Cell Therapy markets despite current COVID-19 travel restrictions. The Company successfully delivered sales of $27K in developer kits through its distributor in China and Czech Republic and achieved sales of $31K for the quarter ended 31 December 2020.
Ongoing improvements to the chip performance and efficiency activity continue to dominate the cash outflow over the last 2 quarters. During the quarter, R&D expenditure and staff costs continue to be amongst the major cash outflow items - $361K and $513K respectively. The company expects to receive a refund for both activities of 43.5% in the form of 2020/2021 R&D Tax Incentive from the Australian Governmen